Following the rules: Five regulatory updates for the supplement industryFollowing the rules: Five regulatory updates for the supplement industry
Join former FDA employee and current Faegre Baker Daniels counsel Jason Sapsin for a discussion about the current legal issues affecting the supplement industry.
November 28, 2018

“We all have a vested interest in maintaining and improving the public’s perception of the safety of dietary supplements. The industry does not run without consumer confidence.”
— Jason Sapsin, Counsel, Faegre Baker Daniels
Highlights:
With CBD products, you can be prosecuted at any time for any level of THC.
Probiotics have never been actually approved by the FDA for any therapeutic indication: the stronger your claims, the more likely you’ll be targeted.
New dietary ingredients (NDI) are probably the lowest level of concern; currently, there’s no enforcement.
The FDA has jurisdiction over roughly 20-25 cents of every dollar spent by every consumer in the U.S.—an enormous regulatory footprint.
Learn why Medicare Advantage may represent the single greatest opportunity for dietary supplement manufacturers and distributors in the last 5-10 years.
This session—The Supplement Round Table: Regulatory Updates—was recorded at Natural Products Expo East 2018. Click "download" to access the presentation slides.
You May Also Like